Goal-directed Therapy in High-risk Surgery
2012年9月5日 更新者:Xiangcai Ruan、Guangzhou First People's Hospital
A Randomized Study of Goal-directed Therapy in the Elderly High-risk Patients Undergoing Total Hip Replacement
There is growing evidence that the risk of postoperative complications can be decreased by optimizing the amount and type of infusion fluids given during surgery, steered by goal-directed therapy based on flow-related hemodynamic parameters, particularly in high-risk patients.
This study is undertaken subsequently to test the hypothesis that the intraoperative goal-directed strategy based on FloTrac/Vigileo, a minimally invasive monitor, can partially prevented postoperative complications and shorten hospital stay in the elderly high-risk patients undergoing total hip replacement with continuous spinal anaesthesia .
研究概览
详细说明
After sedated with IV 0.02 mg/kg midazolam, all patients will receive arterial, central venous, and L3-4 intrathecal catheterizations.
A T12 sensory level block was attained with ropivacaine through the intrathecal catheter.
Besides currently recommended monitoring during the intraoperative period, arterial blood pressure, stroke volume (Edwards Lifesciences, Irvine, Calif.), and central venous oxygen saturation (Edwards Lifesciences) will be measured and recorded.
All Patients will receive intranasal oxygen 2 mL/min and be kept normothermic (body temperature > 36°C).
Patients in both groups receive 8 mL/kg/hour of Ringer's lactate solution from 30 minutes prior to induction of anaesthesia through the end of surgery, when the rate will be decreased to 100 mL/hour.
In addition, boluses of colloid will be given to different protocol group according to the study arm to which the patient allocated.Postoperative care and discharge criteria were predefined using the hospital care map and protocol.
研究类型
介入性
注册 (预期的)
72
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510180
- Guangzhou First Municipal People's Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
70年 及以上 (年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- 1. Adult patients scheduled for total hip replacement at this institution.
- 2. American Society of Anaesthesiologists (ASA) physical status of III or VI.
- 3. Two or more risk factors according to risk index of Lee .
Exclusion Criteria:
- 1. Age under 70years old
- 2. idiopathic coagulopathy: with warfarin or heparin
- 3. systemic or local infection
- 4. unable to cooperate
- 5. spinal trauma or severe low back pain history
- 6. patient refusal.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Protocol group 1
Using standard hemodynamic therapy
|
The goal of this protocol is to ensure MAP> 65 mmHg, CVP 8-12 cmH2O.
If meet the above requirements, do nothing, re-evaluate after 5min.
If CVP <8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal.
If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution.
Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
其他名称:
|
|
实验性的:Protocol group 2
Using goal-directed therapy
|
ensure SpO2≥ 92%, MAP 65-100 mmHg, HR <100 bpm, Hb> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge.
The fluid challenge repeat until the SV failed to increase by a factor of 10%.
If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given.
Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia.
Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
length of postoperative hospital stay
大体时间:28 days
|
days from end of surgery to hospital discharge.
|
28 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
postoperative complications and mortality
大体时间:28 days
|
|
28 days
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
information of hemodynamic and ScvO2 ,types and volumes of all fluids administered
大体时间:24 hours after operation
|
24 hours after operation
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Xiangcai Ruan, MD, PHD、Guangzhou First Municipal People's Hospital,Guangzhou Medical College
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Gan TJ, Soppitt A, Maroof M, el-Moalem H, Robertson KM, Moretti E, Dwane P, Glass PS. Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology. 2002 Oct;97(4):820-6. doi: 10.1097/00000542-200210000-00012.
- Mayer J, Boldt J, Wolf MW, Lang J, Suttner S. Cardiac output derived from arterial pressure waveform analysis in patients undergoing cardiac surgery: validity of a second generation device. Anesth Analg. 2008 Mar;106(3):867-72, table of contents. doi: 10.1213/ane.0b013e318161964d.
- Cecconi M, Fasano N, Langiano N, Divella M, Costa MG, Rhodes A, Della Rocca G. Goal-directed haemodynamic therapy during elective total hip arthroplasty under regional anaesthesia. Crit Care. 2011;15(3):R132. doi: 10.1186/cc10246. Epub 2011 May 30.
- Lees N, Hamilton M, Rhodes A. Clinical review: Goal-directed therapy in high risk surgical patients. Crit Care. 2009;13(5):231. doi: 10.1186/cc8039. Epub 2009 Oct 26.
- Moore JM. Continuous spinal anesthesia. Am J Ther. 2009 Jul-Aug;16(4):289-94. doi: 10.1097/MJT.0b013e3181729d2a.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2012年9月1日
初级完成 (预期的)
2013年6月1日
研究完成 (预期的)
2013年6月1日
研究注册日期
首次提交
2012年9月5日
首先提交符合 QC 标准的
2012年9月5日
首次发布 (估计)
2012年9月7日
研究记录更新
最后更新发布 (估计)
2012年9月7日
上次提交的符合 QC 标准的更新
2012年9月5日
最后验证
2012年9月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.